Bergen Brunswig supply channel cost-control is focus after merger called off.
This article was originally published in The Tan Sheet
Executive Summary
BERGEN SUPPLY EFFICIENCIES WILL REMAIN FOCUS AFTER COLLAPSE OF IVAX MERGER agreement, the wholesaler commented March 20. "One of Bergen Brunswig's central strategies is to pursue opportunities to manage supply channel costs" through in-house programs, alliances or acquisitions, Bergen said. "Notwithstanding the termination of the Ivax agreement, we will continue to pursue our strategy, recognizing the valuable role that generics play."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning